Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.

导出 LinkOut

翻译打印收藏纠错

作者： Bertram,Glass ^[1] ; Justin,Hasenkamp ^[2] ; Gerald,Wulf ^[2] ; Peter,Dreger ^[3] ; Michael,Pfreundschuh ^[4] ; Martin,Gramatzki ^[5] ; Gerda,Silling ^[6] ; Christian,Wilhelm ^[7] ; Matthias,Zeis ^[1] ; Anke,Görlitz ^[8] ; Sebastian,Pfeiffer ^[8] ; Reinhard,Hilgers ^[9] ; Lorenz,Truemper ^[2] ; Norbert,Schmitz ^[10] ; German High-Grade Lymphoma Study Group

作者单位： Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Hospital St Georg, Hamburg, Germany. ^[1] Department of Hematology & Oncology, University Medicine Goettingen, Goettingen, Germany. ^[2] Department of Medicine V, University of Heidelberg, Heidelberg, Germany. ^[3] Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany. ^[4] Medical Clinic II, Section for Stem Cell Transplantation and Immunotherapy, University Clinic Schleswig-Holstein, Kiel, Germany. ^[5] Center for Bone Marrow Transplantation, University Clinic Muenster, Muenster, Germany. ^[6] Clinic for Hematology, Oncology and Immunology, University Clinic Giessen and Marburg, Marburg, Germany. ^[7] Institute of Application-oriented Research and Clinical Trials, University Medicine Goettingen, Goettingen, Germany. ^[8] Institute of Medical Statistics, University Medicine Goettingen, Goettingen, Germany. ^[9] Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Hospital St Georg, Hamburg, Germany. Electronic address: n.schmitz@asklepios.com. ^[10]